Chimerix (CMRX) Posts Earnings Results, Beats Estimates By $0.09 EPS
Chimerix (NASDAQ:CMRX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09, Fidelity Earnings reports. Chimerix had a negative return on equity of 34.94% and a negative net margin of 1,582.64%. The business had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $0.97 million.
Chimerix stock traded down $0.17 during midday trading on Friday, reaching $3.32. 84,193 shares of the company were exchanged, compared to its average volume of 215,341. The stock has a market cap of $172.41 million, a PE ratio of -2.20 and a beta of 1.20. Chimerix has a 1 year low of $3.11 and a 1 year high of $5.94.
A number of research analysts have recently weighed in on the company. Cowen restated a “hold” rating and issued a $6.00 price target on shares of Chimerix in a research report on Thursday, October 18th. Zacks Investment Research cut Chimerix from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Chimerix in a research report on Friday, September 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $6.75.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
See Also: Bear Market
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.